Business
Altruist Biologics' Hangzhou Facility Secures First Commercial Manufacturing License
Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced that its Hangzhou facility was granted the Drug Product Manufacturing License (C Certificate) from the Chinese National Medical Products Administration (NMPA). This is the first certificate awarded to a 20,000-liter scale biologics manufacturing facility in China, confirming that its quality systems, GMP facilities, and technologies meet the rigorous requirem
About this update from Innovent Biologics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"First GMP manufacturing license granted to a manufacturing facility in China with four 20,000 liter-scale bioreactors, marking an important milestone in Altruist's expanding service capabilities.","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Only two months from facility qualification to licensure, demonstrating the company's commitment to outstanding technical capabilities and a rigorous quality management system that upholds international standards.","length":217,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":416,"olType":false},{"type":"text","content":"HANGZHOU, China, April 8, 2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced that its Hangzhou facility was granted the Drug Product Manufacturing License (C Certificate) from the Chinese National Medical Products Administration (NMPA). This is the first certificate awarded to a 20,000-liter scale biologics manufacturing facility in China, confirming that its quality systems, GMP facilities, and technologies meet the rigorous requirements of regulatory health authorities for drug production quality management.","length":629,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/2640ddda0558d5f1efcf425f90e2343f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jZXYDSlPFe9NMLdv9PA.Jg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MQ--/https://media.zenfs.com/en/prnewswire.com/2640ddda0558d5f1efcf425f90e2343f","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2950325/image.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics, commented, "We're pleased that our Hangzhou facility successfully achieved the C Certificate for biologics commercial manufacturing. This represents another remarkable milestone in our efforts to establish premier-quality operations and fully integrated services to support our clients' commercialization goals. We look forward to supporting the development and manufacture of more life-saving treatments for ...